Immune-Related lncRNAs to Construct Novel Signatures and Predict the Prognosis of Rectal Cancer

Frontiers in Oncology

Yuan-Wu Liu¹  Chaoqun Xing²  Zhi-Yong Yao²  Xiao-Liang Xing²  Zhi Huang² 

[1] Beijing Advanced Innovation Center for Food Nutrition and Human Health, China Agricultural University, Beijing, China;Department of Pediatrics, Xiangya Hospital, Central South University, Changsha, China;School of Public Health and Laboratory Medicine, Hunan University of Medicine, Huaihua, China;

关键词: READ;    immune;    LncRNAs;    overall survival;    risk model;   

DOI  :  10.3389/fonc.2021.661846

来源: DOAJ

【 摘 要 】

Colorectal cancer (CRC) is one of the most common cancers. Almost 1/3 of CRC are rectal cancer, and 95% of rectal cancers are rectal adenocarcinoma (READ). Increasing evidences indicated that long noncoding RNAs (lncRNAs) have important role in the genesis and development of cancers. The purpose of our present study was to identify the differential expression lncRNAs which potentially related with immune cells infiltration and establish a risk assessment model to predict the clinical outcome for READ patients. We obtained three immune-related differential expression lncRNAs (IR-DELs) (C17orf77, GATA2-AS1, and TPT1-AS1) by differential expression analysis following correlation analysis and Cox regression analysis. A risk assessment model were constructed by integrating these analysis results. We then plotted the 1-, 3-, and 5-year ROC curves depending on our risk assessment model, which suggested that all AUC values were over 0.7. In addition, we found that the risk assessment model was correlated with several immune cells and factors. This study suggested that those three signatures (C17orf77, GATA2-AS1, and TPT1-AS1) screened by pairing IR-DELs could be prognosis markers for READ patients and might benefit them from antitumor immunotherapy.

【 授权许可】

Unknown